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European Journal of Cardio-thoracic Surgery 40 (2011) 749—755AbstractObjective: The ATS 3f EnableW Bioprosthesis is a self-expanding valve with a tubular design that allows for decreased leaflet stress and
preservation of aortic sinuses. We report themidterm results of a prospective, multicenter clinical study evaluating the safety and efficacy of this
stented bioprosthesis in patients undergoing isolated aortic valve replacement with or without concomitant procedures. Methods: A total of 140
patients (mean age: 76  6 years; 63% of patients in New York Heart Association (NYHA) stage III—IV) received the ATS 3f EnableW Bioprosthesis in
10 European centers between March 2007 and December 2009. The total accumulated follow-up is 121.8 patient-years. Results: Valve
implantation resulted in significant improvement of patients’ symptoms. Mean systolic gradient was 9.04  3.56 and 8.62  3.16 mmHg with
mean effective orifice area of 1.69  0.52 and 1.67  0.44 at 6 months and 1 year, respectively. No significant transvalvular aortic regurgitation
was observed. Early complications included three major paravalvular leaks (PVL; 2.1%) resulting in valve explantation and one thrombo-embolic
(0.7%) event. All, but one, of the early PVLs were evident intra-operatively with the medical decision made not to reposition or resolve
immediately. Late adverse events included three explantations (2.5% per patient-year): one due to PVL and two due to endocarditis. There was an
additional case of late endocarditis (0.8% per patient-year) that resolved by medical management. No structural deterioration, valve-related
thrombosis or hemolysis was documented. Conclusions: The sutureless valve implantation technique is feasible and safe with the ATS 3f Enable
Bioprosthesis. Valve implantation resulted in excellent hemodynamics and significant clinical improvement. Overall, these data confirm the
safety and clinical utility of the EnableW Bioprosthesis for aortic valve replacement.
# 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Degenerative valvular diseases, including aortic valve
stenosis (AS), represent a growing health-care issue around
the [1] globe. Surgical replacement of the aortic valve (AVR)
is the only treatment modality that consistently increases
survival rates in case of hemodynamically significant orifice
narrowing [2]. Historically, AVR has been contraindicated in
elderly and high-risk patients because of the negative effects
of full sternotomy, cardiopulmonary bypass and cardioplegic§ Presented at the 24th Annual Meeting of the European Association for
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approaches, such as partial sternotomy and the development
of novel bioprostheses, an increasing number of high-risk
subjects are being considered for surgical management [3—
5]. Of note, reducing surgical trauma by smaller incision
proved to be highly beneficial despite the fact that minimally
invasive techniques are often associated with impaired
visualization of the aortic root and may prolong cardiopul-
monary bypass and cross-clamp times, at least during the
surgeon’s initial learning curve [5,6]. For implantation
through minimally invasive approaches, and with the
intention to shorten long multi-target procedures, sutureless
bioprostheses merit special interest.
The increasing demand for bioprostheses with limited
surgical burden, yet with excellent hemodynamic profile,
prompted the development of the ATS 3f EnableW Model 6000
(ATS Medical Inc., Minneapolis, MN, USA) ‘sutureless’ valve.
The basic structure of the valve is identical to its predecessor,Surgery. Published by Elsevier B.V. All rights reserved.
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Inc., Minneapolis, MN, USA), but a nitinol frame has been
added allowing for sutureless implant [7,8].
The first clinical results with the early version of the new
ATS 3f EnableW Aortic Bioprosthesis Model 6000 sutureless
valve were reported by Wendt et al. in 2008 [9]. After careful
review of this initial data, modifications to the flange were
performed resulting in the second generation of the valve
[10]. To evaluate the safety and clinical performance of the
bioprosthesis, a prospective, multicenter clinical trial was
initiated. Single-center experiences were published in 2009
and 2010 [10—12]; the minimally invasive approach using
partial sternotomy was first reported in 2010 [13]. It is the
objective of this report to present the intermediate data of
this prospective, multicenter clinical study enrolling patients
at 10 European investigational sites.2. Patients and methods
2.1. Device description
The device is assembled from three equal sections of
equine pericardial tissue using locking sutures (Fig. 1). The
interlocking, adjacent leaflets form a tubular structure and
result in three, equally spaced commissural tabs that are
reinforced with polyester material. All equine tissues are
pre-treated with glutaraldehyde under specific conditions
(e.g., critical treatment time, pH, and temperature). This[()TD$FIG]
Fig. 1. Photo of the ATS 3f EnableW Aortic Bioprosthesis Model 6000.fixation process preserves the architecture of the collagen
matrix thus maintaining tissue strength and flexibility,
minimizes immunogenicity and reduces thrombogenic poten-
tial [7,8]. A self-expanding nitinol frame covered with
polyester fabric on the inflow aspect has been added to the
design of the ATS 3f EnableW Model 6000 bioprosthesis. The
internal properties of nitinol and the flexibility of the pre-
treated equine pericardial leaflets allow the device to be
folded and to be positioned appropriately within minutes
intra-operatively. Upon deployment, its shape and size return
to the preset dimensions and the outward radial forces
inherent to the thermal memory of the nitinol frame keep the
valve fixed at the target position, preventing it from
migration. As such, only a single guiding suture, if any,
may be necessary to secure the valve to the annulus. The
polyester flange at the inflow aspect promotes tissue in-
growth and thus contributes to the long-term stabilization of
the valve.
2.2. Patient population
A total of 140 patients (53 males, 87 females; mean age:
76.1  5.7 years) were enrolled into this prospective, inter-
national, multicenter, non-randomized study. Participants
were implanted with the novel ATS 3f EnableW Sutureless
Bioprosthesis between March 2007 and December 2009 at one
of the 10 participating European investigational sites: (1)
Johann Wolfgang Goethe University (Frankfurt, Germany);
(2) Jagiellonian University (Krakow, Poland); (3) University
Hospital Bern (Bern, Switzerland); (4) John Radcliffe Hospital
(Oxford, UK); (5) UKSH, Campus Lubeck (Lubeck, Germany);
(6) University Medical Center Freiburg (Freiburg, Germany);
(7) Medical University of Gdansk (Gdansk, Poland); (8)
University Medical Center Kiel (Kiel, Germany); (9) Medical
University Vienna (Vienna, Austria); and (10) University
Hospital Basel (Basel, Switzerland).
Patients requiring isolated AVR with or without concomi-
tant procedures were eligible to participate. Patients
requiring valve replacement other than the aortic valve,
subjects with previously implanted prosthetic heart valve(s,)
and/or rigid annuloplasty ring in the mitral position were
excluded from the study. Preoperative exclusion criteria
included active endocarditis or other systemic infections;
pathologies potentially leading to irregular geometry of the
ascending aorta, and life expectancy less than or equal to 24
months at the time of the surgery. Patients younger than
20 years of age, those not willing to return to the implant
center to complete the required follow-up visits, alcohol
and/or intravenous-drug abusers, and thosewho participated
in concomitant research studies of investigational products
were also excluded. Additional intra-operative exclusion
criteria included abnormal anatomy of the coronary ostia at
high risk for occlusion by the study device, active
endocarditis, and the need for rigid annuloplasty ring
implantation at the mitral position.
The study was conducted according to the applicable local
and international regulatory requirements and was approved
by the local Ethics Committee at each investigational site. All
patients enrolled in the study were informed adequately
regarding the investigational status of the device, the
associated benefits and risks, and the availability of
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Table 1. Pre-operative patient demographics.
Variable Category Study cohort
n = 140
Age at implantation (years) 76.1  5.7 —
Body mass index (BMI) 28.3  4.7 —
Variable Category N %
Gender Male 53 38
Female 87 62
Previous
cardiac surgery
Yes 29 21
No 111 79
Valvular lesion Stenosis 99 71
Insufficiency 5 4
Mixed 36 26
Pre-existing
medical conditions
Angina 21 15
Cardiac arrhythmia 37 26
Cardiomyopathy 5 4
Carotid artery disease 24 17
Coronary artery disease 77 55
Diabetes mellitus 43 31
History of endocarditis 2 1
Hyperlipidemia 64 46
Hypertension — pulmonary 22 16
Hypertension — systemic 120 86
Mitral insufficiency 32 23
Obesity 29 21
Smoking 26 19
TIA 6 4
Chronic obstructive
lung disease
20 14
Tricuspid insufficiency 13 9alternative treatment options. A written informed consent
was obtained from all participants.
2.3. Procedure
Complete median sternotomy was performed for 112
patients (80%); 28 subjects (20%) underwent partial upper
sternotomy (a less invasive approach). Following cardiopul-
monary bypass and cardioplegic arrest, the aortic valve was
exposed through transverse aortotomy and the native valve
was excised under direct observation. The ATS sutureless
bioprosthesis was positioned and deployed at the target
location. A detailed description of the entire surgical
procedure has been published previously [11]. Intra-opera-
tive transesophageal echocardiogram (TEE) was routinely
performed to verify correct valve positioning and to assess
the hemodynamic performance of the valve.
2.4. Follow-up
Patient safety and the performance of the ATS 3f EnableW
Model 6000 Bioprosthesis were assessed through regularly
scheduled follow-up visits. A complete physical examination,
routine chemistry panel, and TTEwere performed at the time
of hospital discharge, at 3—6, 11—14 months post-surgery,
and annually thereafter. Hemodynamic parameters were
assessed via TTE by two-dimensional, M-mode, pulsed-wave
and color-flow imaging. All echocardiographic data were
forwarded to an independent core laboratory. Adverse events
were reported as ‘early’ if detected within 30 days of surgery
and ‘late’ if documented subsequently.
2.5. Statistical analysis
Descriptive statistics are presented for baseline demo-
graphic, clinical, and operative parameters. Hemodynamic
parameters were expressed as mean  standard deviation.
Estimates for both early (within 30 days of the implant
procedure) and late (greater than 30 days post implant)
adverse events are provided. Early adverse event rates were
calculated by dividing the number of events by the total
number of patients. Late adverse event rates were expressed
as linearized rates and were calculated by dividing the
number of events by the length of follow-up in patient-years.
Kaplan—Meier estimates for cumulative survival from valve-
related mortality and total mortality at 1 year are presented.
Change in NYHA class was tested for statistical significance
using a paired t-test. All analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC, USA).3. Results
3.1. Patient and procedure characteristics
Patient demographics and operative details are summar-
ized in Tables 1 and 2. The indication for the surgery included
degenerative native aortic valve disease (113 patients;
80.8%); rheumatic heart disease (24 patients; 17.1%);
abnormality related to prior endocarditis (one patient;
0.7%), and other aortic valve pathology (two patients;1.4%), as indicated in Fig. 2. The total accumulated follow-up
was 121.8 patient-years, as of the cut-off date for the
present report.
Implantation of the ATS 3f EnableW Model 6000 Bioprosth-
esis was successful using only a single guiding suture in 85.6%
of patients. Mean aortic cross-clamp and cardiopulmonary
bypass times were noted as 58.1  25.1 and 84.9  34.2 min,
respectively. Two of the centers reported average cross-
clamp and cardiopulmonary times as low as 36.8  7.7 and
54.8  11.5 for their stand-alone procedures (n = 34).
Concomitant procedure was performed for 42 patients
(30% of all study participants), with coronary artery bypass
grafting (18.6%) and left atrial appendage closure (3.6%)
being the most frequent. The following sizes were used in the
present study: 19 mm (four patients), 21 mm (37 patients),
23 mm (42 patients), 25 mm (36 patients), 27 mm (16
patients), and 29 mm (five patients).
3.2. Early and late adverse events
Five patients (3.6%) died within 30 days of surgery; two of
these deaths were classified as valve related (1.4%): one
participant died of multi-organ failure and one of bi-
ventricular heart failure. Of note, both deaths were classified
as events with unknown etiology by the Principal Investiga-
tors, thus leading to the automatic re-classification of these
events as valve related. Early non-fatal adverse events were
limited to cerebrovascular accident in a single patient (0.7%),
major paravalvular leak (PVL) prompting valve explantation
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Table 2. Operative patient demographics.
Variable Category Total population
n = 140 %
Exposure techniques (sternotomy) Conventional sternotomy 112 80
Minimally invasive sternotomy 27 19
Other 1 1
Opening of the aorta (aortotomy) Complete aortic transection 5 4
Partial aortic transection 135 96
Concomitant procedures (data are not mutually exclusive) None 98 70
Coronary artery bypass 26 19
Left atrial appendage closure 5 4
Annuloplasty 1 1
Subvalvular myectomy 6 4
Left atrial ablation 4 3
Aortic surgery 3 2
Cardioplegia Cold 112 80
Warm 0 0
Both 28 20
Cardioplegia delivery Antegrade 103 74
Retrograde 2 1
Both 35 25
Condition of ascending aorta Normal 112 80
Calcified 14 10
Dilated 14 10
Condition of annulus (data are not mutually exclusive) Normal 11 8
Calcified 126 90
Fibrotic 20 14
Friable 3 2
Extent of debridement None 1 1
Minimum 6 4
Moderate 48 34
Average 68 49
Extreme 17 12
Subvalvular aortic stenosis None 127 91
Dynamic 1 1
Idiopathic hypertrophic subaortic 10 7
Indeterminate 2 1
Number of sutures (n = 139) 0 17 12
1 119 86
2 or more 3 2in three subjects (2.1%), and minor PVL not requiring surgical
intervention in three patients (2.1%). All, but one early PVLs
were evident intra-operatively, but the medical decision was
made by the surgical team not to reposition the bioprosthesis
or resolve the leak by other means immediately.
Thirteen patients died in the late postoperative period; a
valve-related cause was identified in two of these subjects
(1.6% per patient-year; both sudden cardiac deaths).
Cumulative freedom from valve-related mortality was
[()TD$FIG]Fig. 2. Indication for surgery in our study population (n = 140).96.5% at 1 year and freedom from total mortality was
85.1% during the same reporting period. Late adverse events
included major PVL in one patient prompting valve
explantation (0.8% per patient-year). Endocarditis was
diagnosed in three cases (2.5% per patient-year); among
those patients, valve explantation was unavoidable for two
subjects, while the third patient was managed medically and
responded well to the therapy. No structural prosthetic
deterioration, valve thrombosis, hemolysis, or clinically
significant transvalvular aortic regurgitation occurred during
the follow-up period.
3.3. Hemodynamic parameters
TTE was performed and hemodynamic parameters were
obtained at the time of hospital discharge and at regularly
scheduled outpatient visits at 3—6 and 11—14 months post-
surgery. Echocardiographic results are presented in Table 3.
The average mean aortic gradient was measured at
10.2 mmHg at the time of discharge, 9.0 at 3—6 months,
and 8.6 mmHg at 11—14 months. Accordingly, the average
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Table 3. Hemodynamic parameters during the study period, as measured by transthoracic echocardiography.
Discharge Post-implantation
3—6 months 11—14 months
Mean gradient (mmHg) 10.24  4.20 9.04  3.56 8.62  3.16
Peak gradient (mmHg) 20.34  8.15 18.21  6.89 16.44  6.00
Effective orifice area (cm2) 1.75  0.45 1.69  0.52 1.67  0.44
Indexed effective orifice area (cm2/m2) 0.98  0.26 0.92  0.28 0.92  0.24
Left ventricular cardiac output (l/min) 5.20  1.16 4.57  1.11 4.48  1.00
Left ventricular cardiac index (l/min m2) 2.92  0.65 2.51  0.66 2.47  0.60
[()TD$FIG]
Fig. 3. The effect of aortic valve replacement with the ATS 3f EnableW Aortic
Bioprosthesis Model 6000 on the New York Heart Association (NYHA) functional
capacity. Pre-operative and 11—14 months post-operative data are shown. The
improvement in the NYHA functional classification is highly significant at
p < 0.0001.peak systolic gradient decreased from 20.3 to 18.2 mmHg and
then to 16.4 mmHg by the end of the first postoperative year.
The following parameters were also measured and the
average values at the time of discharge, 3—6, and 11—14
months follow-up visits were collected: effective orifice area
(1.75  0.45 vs 1.69  0.52 vs 1.67  0.44 cm2); indexed
effective orifice area (0.98  0.26 vs 0.92  0.28 vs
0.92  0.24 cm2 m2); cardiac output (5.20  1.16 vs
4.57  14.11 vs 4.48  1.00 l min1); cardiac index
(2.92  0.65 vs 2.51  0.66 vs 2.47  0.6 l min1 m2).
3.4. Effect of AVR on the New York Heart Association
(NYHA) functional capacity
The NYHA functional capacity was evaluated and recorded
preoperatively and at all subsequent visits. As shown in Fig. 3,
more than 62% of patients were categorized as NYHA Class III or
IV at the pre-implantation assessment and merely 5.7% fell in
the Class I group. By contrast, 98.8% of patients reported NYHA
Class I and II symptoms at the 1-year follow-up visit, with only a
single patient remaining symptomatic atminimal activity (Class
III). These data represent a significant (p < 0.001) improve-
ment in the functional capacity ofmost patients undergoingAVR
with the ATS 3f EnableW Model 6000 Aortic Bioprosthesis.4. Discussion
The excellent operative results obtained with stented and
stentless bioprosthetic valves to treat severe aortic stenosis
in the elderly population promote their broad usage.Implantation of a stented valve is technically less demanding
and the hemodynamic advantage of stentless valves are yet
controversial with regard to the postoperative transpros-
thetic gradient and regression of the left ventricular
hypertrophy [15]. As such, surgeons who would prefer the
performance of a stentless valve may be dissuaded from its
use because of the technical difficulty and extra surgical time
required by some models. Thus, there is an ongoing effort to
develop and evaluate novel devices and surgical techniques
for the management of these high-risk patients. The present
report summarizes the results of a multicenter, interna-
tional, prospective clinical trial with the ATS 3f EnableW
Model 6000 Aortic Bioprosthesis, the first commercially
available sutureless bioprosthesis for conventional AVR. Ten
European investigational sites participated in the study,
which was conducted before CE approval in 2010.
The idea of a sutureless valve in the aortic position was
first introduced by McGovern et al. in the early 1960s; they
presented clinical results with a ball-cage-type mechanical
valve [16]. The high incidence of disabling thrombo-
embolism (42%) and re-operation (16%), however, precluded
the routine adaptation of these early models [17]. Forty years
later, Wendt and colleagues published the initial clinical
experience with the novel, ATS 3f EnableW Aortic Bioprosth-
esis developed for sutureless implantation [9]. In their early
experience, three out of six patients presented with
paravalvular leak at follow-up visits. Because of this
unfavorable observation, the initial design was modified
and the inferior aspect of the polyester flange was enlarged
allowing for broader interface with the annulus. In addition,
the need for three ‘stay sutures’ was eliminated, which may
have caused distortion of the implant. These structural
changes led to a dramatic reduction in the incidence of
paravalvular leak; however, exact positioning of the ATS 3f
EnableW Aortic Bioprosthesis remains critical.
The self-expanding nature of the nitinol frame has the
potential to facilitate faster deployment and valve implanta-
tion. The bypass and aortic cross-clamp times reported in the
present series are shorter, but not statistically different from
those reported for other stented bioprostheses [15,18,19]. It
is important to note, however, that procedural time relates
inversely with the experience of the surgical team, and data
from experienced centers indicate that the above times can
be significantly reduced to as low as 36.8  7.7 and
54.8  11.5 min for stand-alone procedures, respectively.
In our opinion, additional modifications to the polyester
flange allowing for broader coaptation with the native
annulus and enhanced positioning of the valve would further
reduce procedural time. In addition, a minimally invasive
approach via partial upper sternotomy is feasible with the
S. Martens et al. / European Journal of Cardio-thoracic Surgery 40 (2011) 749—755754ATS 3f EnableW Aortic Bioprosthesis in patients without the
need for additional procedures. This was indeed the access of
choice in approximately one-fifth of all enrolled patients and
yielded good results.
In our hands, the valve proved to be versatile and has
demonstrated good intra-operative handling characteristics.
Early hemodynamic data are encouraging and are compar-
able with conventional stented valves [15,18—22]. The
effective orifice area, indexed effective orifice area, cardiac
output, and cardiac index exhibited a slight decrease over
the follow-up period, which is consistent with reports on
other stented valves [18—22]. Of critical importance, a
significant and persistent improvement was documented in
the NYHA functional status of the majority of patients
undergoing AVR with the ATS 3f EnableW Bioprosthesis.Early
fatal complications were limited to 3.5%, including two
valve-related and three non-valve related deaths. Early non-
fatal complications were documented in 4.9% of the cohort.
Late adverse events were recorded at 3.3% per patient-year
during the follow-up period, and these included endocarditis
and major PVL. An important lesson learned in this trial is
that significant PVLs noted by intra-operative echocardio-
gram should always be treated during the index procedure.
Patients leaving the operating room with good echocardio-
graphic results are highly unlikely to develop PVL. The issue
of PVL often associated with sutureless techniques has also
been addressed by other groups working with a different
device [23—25].
In addition, no structural prosthetic deterioration, valve
thrombosis, mechanical hemolysis, or significant transvalv-
ular aortic regurgitation occurred during the study period.
Cumulative freedom from valve-related mortality was 96.5%
at 1 year. As noted in Table 2, no suture was applied in 17
cases and only a single guiding suture was used in 119 of the
140 participants. However, no valve migration (movement of
the valve from its original locus) or tilting was noted post-
implantation. Given the unique design of the bioprosthesis,
ostial blockage of the coronary arteries was not documented.
In the present study, surgical complications and adverse
event rates were comparable to those observed with any
other commercially available stented aortic valves [18—22].
The long-term durability of the valve in the clinical setting is
yet to be determined.
Interest in less invasive valve procedures is primarily
driven by the expected benefit for the patient, including
achievement of the same quality of treatment with reduced
operative mortality and morbidity. Besides the possible
facilitation of minimally invasive approaches, this valve may
also be advantageous for patients needing AVR replacement
along with concomitant procedures that prolong cardiopul-
monary bypass and aortic cross-clamp times, such as
coronary artery bypass grafting.
Catheter-based aortic valve implantation is a new
technique developed for high-risk patients not suitable for
conventional cardiac surgery. Sutureless valve implantation
via partial sternotomy may be considered in this population,
especially if clinical follow-up data confirm the encouraging
initial results described here and cross-clamp times can be
reduced with increasing experience. Potential advantages
versus the catheter-based techniques include the direct view
of the aortic valve enabling its complete resection,decalcification of the aortic annulus, and the safe placement
of the new implant under direct visualization. On the
contrary, cardiopulmonary bypass and cardioplegic arrest are
unavoidable with this approach. Further large case clinical
studies will be required to compare the safety, efficacy, and
long-term outcome of the two methodologies.
In summary, the ATS 3f EnableW Model 6000 Aortic
Bioprosthesis has a safe clinical profile combined with good
and sustainable hemodynamics. Clinical improvement in
virtually all patients’ functional status is demonstrated and is
in line with the observed hemodynamic performance. The
primary benefit of this aortic bioprosthesis is the potential for
surgeons to provide the same gold standard outcomes of
traditional surgical AVR but without the need for sutures,
thereby facilitating less invasive or minimally invasive
procedures. Our multicenter study continues and documents
the long-term performance, durability, and safety profile of
this bioprosthesis.
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Appendix A. Conference discussion
Dr P. Suwalski (Warsaw, Poland): While reading the manuscript, what first
came to my mind were the special indications applicable to this model of the
valve. First of all, parasternal access, which can be quite difficult for standard
sutured valves, or robotic surgery, for example, as shown during Techno
College in very impressive work from our colleagues from the States, and
narrow roots. Have you tried maybe those kinds of indications? Do you know
any applications in this kind of surgery? That would be exciting to know about
it. On the other hand, even 35 minutes of cross-clamp time is very comparable
to sutured valves. In your experience, what was the main reason requiring that
period of cross-clamping, and what would be the way to take it down to, let’s
say, 15 minutes?
Dr Martens: When presenting this data, there is always the discussion
about why the cross-clamp time isn’t shorter. The most important obstacle at
themoment is the design of the currentmodel, because it really requires exact
placement in the annulus. And as you see on the screen, the newer model
allows for easier implant because it has a broader surface area adapting to the
annulus. That is also the answer to the question with regard to the minimally
invasive approaches. We applied quite a lot of the Enable I valves via partial
sternotomy, and what we found out is that visualization of the annulus is
absolutely mandatory with this model. So to reduce the clamping time, we
have to make the implant easier, allowing for setting it free without correcting
the position afterwards.
And the other point is that we performed very meticulous debridement of
the annulus. We are now discussing with the other centers who are implantingthis valve if this is really necessary or if we should just cut out the leaflets and
leave bigger parts of the annulus, perhaps with calcium. However, I think the
low incidence of paravalvular leakage in the whole cohort is also caused by the
fact that we debrided the annulus. But, on the other hand, that makes the
implantation time longer. So it is the beginning of a discussion, but I absolutely
agree with making the procedure suitable for a minimally invasive approach.
This was, for example, also performed by Volkmar Falk’s group in Zurich, where
a surgeon implanted it via a parasternal approach. We also found out that it is
feasible, but that the design of the valve should be changed, allowing for faster
and easier implant.
Dr O. Alfieri (Milan, Italy): I would like to ask one question. In my
experience, a little bit of a disadvantage of this is that you have to make
your incision in the aorta, your aortotomy, a little bit higher, maybe 1 cm
higher, and this, of course, is making the calcification of the annulus maybe
a little bit more difficult, particularly minimally invasively. With the new
model do have to make the incision as high or you can make your aortotomy
a little bit lower?
Dr Martens: To answer this question, it is absolutely right, because you
have to make the incision higher as in a normal aortic valve replacement
procedure, and with the new model, which is not as high as the old one, you
gain around 5 mm, so you can make the incision slightly lower than before.
However, it is a higher incision than in a standard aortic valve replacement
procedure. As I said before, there is an ongoing discussion whether this
meticulous debridement is necessary with this valve, and we don’t know the
answer at the moment. For the study, for the 140 patients presented here, we
performed the debridement, but now the discussion arises as to whether it is
really necessary to this extent.
Dr Alfieri: Do you tolerate 1+ insufficiency in this valve? Did you notice a
tendency to deterioration of the leaks over time?
Dr Martens: We learned that we shouldn’t tolerate any paravalvular
leakage in the OR. I wouldn’t tolerate any. In the cases I performed in Frankfurt
I haven’t seen any, but we have learned from experience that a +1 aortic
paravalvular regurgitation might increase over time, because the valve is not
exactly positioned. In this situation I would convert the case or place a bigger
valve. But I wouldn’t allow the patient to leave the OR with a paravalvular
leakage. We learned from the three early reoperations, where in two of these
patients the paravalvular leakage was already seen in the OR, and the decision
was taken not to go for a second pump run, and perhaps that decision wasn’t
good.
Dr P. Myken (Gothenburg, Sweden): I understand this study; if you go on to
have robotic surgery or minimally invasive, it is a good valve to use. But if you
continue to do conventional open surgery, would you prefer this valve instead
of a sewing ring just for the 30 minutes and could you comment on your
thoughts of durability?
Dr Martens: Well, we have durability data on the model which is the basis
of this valve. The basis of this valve is the 3f valve, and we have long-term
durability data on this valve now from quite a lot of centers. So as the basis is a
standard valve which is already in clinical use, we think that putting it in a
nitinol stent doesn’t really change the long-term durability. However, we have
to wait for long-term data, that’s for sure.
To your question as to what might be the advantage versus other valves, I
see an advantage. For example, I operated on quite a lot of patients with a
small aortic annulus, and I haven’t seen a comparable small valve which
expands in the annulus and really results in a good orifice area and a low
gradient in a small aortic annulus without performing surgery like root
enlargement. So I really see the advantage of having a fast procedure and to
obtain a good hemodynamic gradient, and the other point is to enable
minimally invasive procedures.
Dr A. Bogers (Rotterdam, The Netherlands): All valve implants that
depend on radial forces have an increased incidence of total heart block. How
is this in your prosthesis?
Dr Martens: I didn’t have the incidence in my slides. We had an incidence
of permanent pacemaker implant in this patient cohort of 7%. So I would say it
is slightly increased versus a standard procedure, but I think not comparable,
for example, to transcatheter valves. So the incidence is 7% pacemaker
implant.
